Advertisement
Advertisement
U.S. Markets open in 6 hrs 13 mins
Advertisement
Advertisement
Advertisement
Advertisement

Surrozen, Inc. (SRZNW)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.1200-0.0800 (-3.64%)
At close: 10:50AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.2000
Open0.8000
Bid0.7200 x N/A
Ask0.8500 x 3000
Day's Range1.9200 - 1.9200
52 Week Range1.9200 - 1.9200
Volume8,044
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Surrozen Reports Third Quarter 2021 Financial Results

    Product Candidates SZN-1326 and SZN-043 Advance Toward Initiation of Clinical Studies in 2022 Expanding and Advancing Discovery Stage Pipeline in Multiple Disease Settings SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported financial results for the third quarter ended September 30, 2021 and

  • GlobeNewswire

    Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

    SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced today that data from its liver disease program, including preclinical studies of SZN-043 showing improved liver metabolic function, were presented during The Liver Meeting 2021, organized by the American Association for the Study of Liver Diseases (AASLD) and held November 1

  • GlobeNewswire

    Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (NASDAQ: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 a.m. ET on Monday, November 22. Interested parties may access the live webcast via the Investors section of the Surrozen website

Advertisement
Advertisement